To take the post-test and claim your CE credit for this session, please visit: https://online.epocrates.com/contextuallink/cme/activity/OQUMHW

This educational initiative is targeted to the community-based multidisciplinary and interprofessional HHT treatment team of primary care physicians, internists, hematologists, oncologists, gastroenterologists, otorhinolaryngologists, allergists, and nurses/nurse practitioners, pharmacists, and physician assistants. Strategically developed to promote community clinician awareness of HHT and galvanize optimization of HHT-associated ID and IDA management, this episode will begin with an overview of HHT epidemiology and pathophysiology, emphasizing diverse disease manifestations and clinical presentation, then move into an appraisal of current guideline recommendations for diagnosing, screening, and treating HHT-associated IDA, with an incisive focus on the role of intravenous (IV) iron as iron replacement therapy. Practical differentiators between currently-available IV iron products, inclusive of total dose infusion (TDI) capacity and relative risk for IV iron-induced hypophosphatemia, will be highlighted and emphasized throughout the activity using practical patient case scenarios.

In this episode of CME-Pod, leading clinical experts - Drs. Truman Milling, Jr, Deborah Siegal, and Geoffrey Barnes - will provide learners with a circumscription of the clinical benefits and risks associated with DOAC usage, inclusive of patient-specific, disease-specific, and drug-specific risk factors, and will examine the unique pharmacologic mechanisms of established and emerging specific reversal therapeutics. A review of the evidentiary base will follow, encompassing completed, ongoing, and planned clinical trials for specific reversal agents, as well as recent readouts and pending regulatory updates that have the potential to meaningfully shift the calculus. The session will conclude with a case-based segment that tangibly highlights the imperative need for multidisciplinary collaboration and the importance of individualized, data-driven treatment selection.

To access the webinar on Healio, complete the post-test and activity evaluation, and claim your CE credit, please follow this link: https://cme.healio.com/cardiology/20240112/optimizing-outcomes-for-patients-with-doac-related-bleeding